San Francisco, CA / December 8, 2008 / –
At the most recent 2008 annual meeting of the American Society of Hematology in San Francisco, on December 8, 2008, Dr Kenneth Kim, WCCT CEO, recently
presented a SAE (serious adverse event) in a
trial recently conducted at WCCT, title “ACE-011, a Soluble Activin Receptor Type IIa IgG-Fc Fusion Protein, Increases Hemoglobin and Hemaocrit Levels in Postmenopausal Healthy Women“. The
may be a serendipitous finding as it demonstrated the test compound had an unexpected effect on hematopoeisis. Further inquires regarding the compound should be directed to Celgene Corporation in Summit, NJ
or Acceleron Pharma in Cambridge, MA.
About West Coast Clinical Trials, LLC
WCCT is an independent early phase clinical CRO with a 120-bed phase I facility with 10 telemetry equipped beds located in southern California. WCCT has a unique focus on Ethno-bridging studies along with extensive experience with healthy volunteer and specialty trials (allergy, asthma, infectious disease, pediatric, renal and vaccines). For more information, visit our Web site at
West Coast Clinical Trials
5630 Cerritos Ave.
Cypress, CA 90630 USA
Phone: (714) 252-0700